Research - Edinburgh, Scotland, United Kingdom
Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developingnovel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.
Outlook
Apache
WordPress.org
Google Font API
Mobile Friendly